Q-Line Biotech Profit & Loss Annual

BSE: - | NSE: QLINE | ISIN: INE1G2W01011 | Sector: Biotechnology & Drugs

651.10 -33.25 (-4.86%)Updated : 08 Oct 2026

Research on

Interim Data

Annual Data

Fiscal Period	2025	2024	2023	2022
Period End Date	Mar 25	Mar 24	Mar 23	Mar 22
Total Operating Expense	524.48	338.11	300.26	461.90
Other Net	3.80	-0.24	-0.58	1.12
Total Adjustmentsto Net Income	0.00	-	-	-
Diluted Weighted Average Shares	2.33	2.33	2.33	2.33
Gain( Loss)on Saleof Assets	0.00	0.39	0.00	-
Depreciation/ Amortization	7.32	3.93	2.14	1.30
Operating Income	103.09	69.18	65.22	146.46
Net Income	56.26	68.90	64.19	110.03
Income Availableto Com Excl Extra Ord	56.26	68.90	64.19	110.03
Other Operating Expenses Total	58.85	46.50	33.72	59.26
Net Income Before Taxes	88.38	61.20	59.68	142.56
Minority Interest	0.00	0.00	0.00	-
Net Income After Taxes	49.03	43.28	42.77	110.03
Income Availableto Com Incl Extra Ord	56.26	68.90	64.19	110.03
Costof Revenue Total	145.67	93.02	88.47	146.26
Gross Profit	168.11	110.63	94.27	157.92
Interest Inc( Exp) Net- Non- Op Total	-11.15	-4.14	-2.19	-3.07
Unusual Expense( Income)	16.97	-	-	-
Diluted Net Income	56.26	68.90	64.19	110.03
Provisionfor Income Taxes	19.68	8.96	8.46	16.27
Equity In Affiliates	3.62	12.80	10.71	-
period Type	-	-	-	-
Net Income Before Extra Items	56.26	68.90	64.19	110.03
Total Revenue	627.56	407.29	365.47	608.36
period Length	12.00	12.00	12.00	12.00
Revenue	313.78	203.65	182.74	304.18
Selling/ General/ Admin Expenses Total	33.44	25.61	25.81	24.13
Diluted Normalized EPS	32.19	29.30	27.52	47.17
Diluted EPS Excluding Extra Ord Items	24.12	29.53	27.52	47.17